Variability in response to albuminuria-lowering drugs: true or random?

British Journal of Clinical Pharmacology

Volumn 83, Issue 6, 2017, Pages 1197-1204

  Petrykiv, Sergei I ^a   de Zeeuw, Dick ^a   Persson, Frederik ^b   Rossing, Peter ^b,c,d   Gansevoort, Ron T ^a   Laverman, Gozewijn D ^e   Heerspink, Hiddo J L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b STENO DIABETES CENTER   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AARHUS UNIVERSITY   (Denmark)

^e TWENTEBORG HOSPITAL   (Netherlands)

Author keywords

albuminuria; drug response; personalized medicine; precision medicine

Indexed keywords

ALISKIREN; ATRASENTAN; ENALAPRIL; LISINOPRIL; LOSARTAN; PARICALCITOL;

ALBUMINURIA; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG EXPOSURE; EFFECT SIZE; HUMAN; MACROALBUMINURIA; MICROALBUMINURIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; TREATMENT RESPONSE; ADULT; AGED; CROSSOVER PROCEDURE; FEMALE; KIDNEY DISEASE; MALE; MIDDLE AGED; REPRODUCIBILITY; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; CROSS-OVER STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 85011545875     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.13217     Document Type: Article

References (35)

1. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 2016; 44: D1054–D1068.
2. Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. Br J Pharmacol 2015; 172: 5744–5869.
3. Alexander SPH, Cidlowski JA, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Nuclear hormone receptors. Br J Pharmacol 2015; 172: 5956–5978.
4. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE, et al. The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 2015; 172: 6024–6109.
5. Schievink B, Zeeuw D, Parving HH, Rossing P, Lambers Heerspink HJ. The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers. Br J Clin Pharmacol 2015; 80: 678–686.
6. Heerspink HJ, Kropelin TF, Hoekman J, Zeeuw D. Drug-induced reduction in albuminuria is associated with subsequent renoprotection: a meta-analysis. J Am Soc Nephrol 2015; 26: 2055–2064.
7. Lambers Heerspink HJ, Gansevoort RT. Albuminuria is an appropriate therapeutic target in patients with CKD: the pro view. Clin J Am Soc Nephrol 2015; 10: 1079–1088.
8. Poortmans J, Dorchy H, Toussaint D. Urinary excretion of total proteins, albumin, and beta 2-microglobulin during rest and exercise in diabetic adolescents with and without retinopathy. Diabetes Care 1982; 5: 617–623.
9. Clerico A, Giammattei C, Cecchini L, Lucchetti A, Cruschelli L, Penno G, et al. Exercise-induced proteinuria in well-trained athletes. Clin Chem 1990; 36: 562–564.
10. Brinkman JW, Zeeuw D, Duker JJ, Gansevoort RT, Kema IP, Hillege HL, et al. Falsely low urinary albumin concentrations after prolonged frozen storage of urine samples. Clin Chem 2005; 51: 2181–2183.
11. Wagner MG, Smith FG Jr, Tinglof BO Jr, Cornberg E. Epidemiology of proteinuria. A study of 4,807 schoolchildren. J Pediatr 1968; 73: 825–832.
12. Rytand DA, Spreiter S. Prognosis in postural (orthostatic) proteinuria: forty to fifty-year follow-up of six patients after diagnosis by Thomas Addis. N Engl J Med 1981; 305: 618–621.
13. Hemmingsen L, Skaarup P. Urinary excretion of ten plasma proteins in patients with febrile diseases. Acta Med Scand 1977; 201: 359–364.
14. Bell KJ, Hayen A, Macaskill P, Craig JC, Neal BC, Fox KM, et al. Monitoring initial response to angiotensin-converting enzyme inhibitor-based regimens: an individual patient data meta-analysis from randomized, placebo-controlled trials. Hypertension 2010; 56: 533–539.
15. Asselbergs FW, Diercks GF, Hillege HL, Boven AJ, Janssen WM, Voors AA, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 2004; 110: 2809–2816.
16. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351: 1941–1951.
17. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870–878.
18. Brenner BM, Cooper ME, Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
19. Gansevoort RT, Zeeuw D, Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861–867.
20. Persson F, Rossing P, Reinhard H, Juhl T, Stehouwer CD, Schalkwijk C, et al. Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial. Diabetologia 2010; 53: 1576–1580.
21. Zeeuw D, Coll B, Andress D, Brennan JJ, Tang H, Houser M, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. J Am Soc Nephrol 2014; 25: 1083–1093.
22. Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551.
23. Laverman GD, Henning RH, Jong PE, Navis G, Zeeuw D. Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria. Am J Kidney Dis 2001; 38: 1381–1384.
24. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008–2013.
25. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994; 12: 1053–1060.
26. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386: 2059–2068.
27. Hellemons ME, Persson F, Bakker SJ, Rossing P, Parving HH, De Zeeuw D, et al. Initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial. Diabetes Care 2012; 34: 2078–2083.
28. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540–1546.
29. Parving HH, Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol 2008; 19: 771–779.
30. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ 2011; 343: d4366.
31. Lambers Heerspink HJ, Oberbauer R, Perco P, Heinzel A, Heinze G, Mayer G, et al. Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. Nephrol Dial Transplant 2015; 30 (Suppl 4): iv105–iv112.
32. Witte EC, Lambers Heerspink HJ, Zeeuw D, Bakker SJ, Jong PE, Gansevoort R. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol 2009; 20: 436–443.
33. Burgess E, Muirhead N. Rene de Cotret P, Chiu A, Pichette V, Tobe S, et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20: 893–900.
34. Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330–337.
35. Vogt L, Waanders F, Boomsma F, Zeeuw D, Navis G. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol 2008; 19: 999–1007.